Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Black Diamond Therapeutics, Inc. (BDTX) since 2020 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Black Diamond Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1701541.
Total stock buying since 2020: $100,368,202.
Total stock sales since 2020: $39,604,330.
Total stock option exercises since 2020: $765,307.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 5,784,292 | $11,967,700 | 0 | $0 |
| 2023 | 4,075,850 | $20,167,590 | 25,000 | $167,500 | 0 | $0 |
| 2022 | 1,635,506 | $4,191,359 | 0 | $0 | 0 | $0 |
| 2021 | 0 | $0 | 52,890 | $1,559,390 | 43,890 | $294,029 |
| 2020 | 3,997,472 | $76,009,253 | 779,314 | $25,909,740 | 63,412 | $471,278 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-03 | 0 | $0 | 5,784,292 | $11,967,700 | 0 | $0 |
| 2023-10 | 400,000 | $934,000 | 0 | $0 | 0 | $0 |
| 2023-07 | 935,850 | $4,679,250 | 0 | $0 | 0 | $0 |
| 2023-06 | 2,740,000 | $14,554,340 | 25,000 | $167,500 | 0 | $0 |
| 2022-12 | 56,363 | $72,361 | 0 | $0 | 0 | $0 |
| 2022-10 | 595,876 | $1,140,203 | 0 | $0 | 0 | $0 |
| 2022-06 | 25,000 | $61,024 | 0 | $0 | 0 | $0 |
| 2022-04 | 958,267 | $2,917,771 | 0 | $0 | 0 | $0 |
| 2021-05 | 0 | $0 | 4,078 | $111,753 | 4,078 | $13,049 |
| 2021-04 | 0 | $0 | 6,578 | $165,797 | 6,578 | $40,199 |
| 2021-03 | 0 | $0 | 6,578 | $173,014 | 6,578 | $40,199 |
| 2021-02 | 0 | $0 | 6,578 | $175,218 | 6,578 | $40,199 |
| 2021-01 | 0 | $0 | 29,078 | $933,608 | 20,078 | $160,383 |
| 2020-12 | 0 | $0 | 21,578 | $721,086 | 23,678 | $160,121 |
| 2020-11 | 0 | $0 | 478,116 | $15,922,158 | 17,578 | $146,339 |
| 2020-10 | 0 | $0 | 242,458 | $8,059,530 | 12,578 | $92,039 |
| 2020-09 | 5,000 | $152,285 | 9,578 | $294,996 | 9,578 | $72,779 |
| 2020-08 | 0 | $0 | 27,584 | $911,970 | 0 | $0 |
| 2020-02 | 3,992,472 | $75,856,968 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-03-19 | Bb Biotech Ag | Sale | 5,784,292 | 2.07 | 11,967,700 |
| 2023-10-17 | Bb Biotech Ag | Buy | 400,000 | 2.33 | 934,000 |
| 2023-07-05 | Shah Rajeev M. | Buy | 935,850 | 5.00 | 4,679,250 |
| 2023-06-30 | Bb Biotech Ag | Buy | 1,000,000 | 5.00 | 5,000,000 |
| 2023-06-27 | Epstein David M. (SEE REMARKS) | Sale | 25,000 | 6.70 | 167,500 |
| 2023-06-27 | Bb Biotech Ag (10% Owner) | Buy | 1,740,000 | 5.49 | 9,554,340 |
| 2022-12-22 | Ni Fang (SEE REMARKS) | Buy | 36,363 | 1.28 | 46,581 |
| 2022-12-21 | Ni Fang (SEE REMARKS) | Buy | 20,000 | 1.29 | 25,780 |
| 2022-10-31 | Bb Biotech Ag (10% Owner) | Buy | 99,801 | 2.25 | 224,951 |
| 2022-10-28 | Bb Biotech Ag (10% Owner) | Buy | 172,974 | 2.18 | 376,910 |
| 2022-10-27 | Bb Biotech Ag (10% Owner) | Buy | 191,678 | 1.87 | 359,204 |
| 2022-10-20 | Bb Biotech Ag (10% Owner) | Buy | 53,734 | 1.42 | 76,356 |
| 2022-10-19 | Bb Biotech Ag (10% Owner) | Buy | 77,689 | 1.32 | 102,782 |
| 2022-06-29 | Ni Fang (SEE REMARKS) | Buy | 25,000 | 2.44 | 61,024 |
| 2022-04-28 | Bb Biotech Ag (10% Owner) | Buy | 255,711 | 2.57 | 657,944 |
| 2022-04-27 | Bb Biotech Ag (10% Owner) | Buy | 150,000 | 2.66 | 399,450 |
| 2022-04-19 | Bb Biotech Ag (10% Owner) | Buy | 150,000 | 3.24 | 486,600 |
| 2022-04-18 | Bb Biotech Ag (10% Owner) | Buy | 150,000 | 3.29 | 493,950 |
| 2022-04-13 | Bb Biotech Ag (10% Owner) | Buy | 102,556 | 3.57 | 366,227 |
| 2022-04-12 | Bb Biotech Ag (10% Owner) | Buy | 150,000 | 3.42 | 513,600 |
| 2021-05-12 | Hatzis-schoch Brent (See Remarks) | Sale | 4,078 | 27.40 | 111,753 |
| 2021-05-12 | Hatzis-schoch Brent (See Remarks) | Option Ex | 4,078 | 3.20 | 13,049 |
| 2021-04-12 | Hatzis-schoch Brent (See Remarks) | Sale | 4,078 | 25.00 | 101,950 |
| 2021-04-12 | Hatzis-schoch Brent (See Remarks) | Option Ex | 4,078 | 3.20 | 13,049 |
| 2021-04-05 | Roberts Christopher D. (Chief Scientific Officer) | Sale | 2,500 | 25.54 | 63,847 |
| 2021-04-05 | Roberts Christopher D. (Chief Scientific Officer) | Option Ex | 2,500 | 10.86 | 27,150 |
| 2021-03-12 | Hatzis-schoch Brent (See Remarks) | Sale | 4,078 | 26.36 | 107,492 |
| 2021-03-12 | Hatzis-schoch Brent (See Remarks) | Option Ex | 4,078 | 3.20 | 13,049 |
| 2021-03-03 | Roberts Christopher D. (Chief Scientific Officer) | Sale | 2,500 | 26.21 | 65,522 |
| 2021-03-03 | Roberts Christopher D. (Chief Scientific Officer) | Option Ex | 2,500 | 10.86 | 27,150 |
| 2021-02-12 | Hatzis-schoch Brent (See Remarks) | Sale | 4,078 | 27.43 | 111,843 |
| 2021-02-12 | Hatzis-schoch Brent (See Remarks) | Option Ex | 4,078 | 3.20 | 13,049 |
| 2021-02-03 | Roberts Christopher D. (Chief Scientific Officer) | Sale | 2,500 | 25.35 | 63,375 |
| 2021-02-03 | Roberts Christopher D. (Chief Scientific Officer) | Option Ex | 2,500 | 10.86 | 27,150 |
| 2021-01-12 | Hatzis-schoch Brent (See Remarks) | Sale | 11,578 | 32.49 | 376,203 |
| 2021-01-12 | Hatzis-schoch Brent (See Remarks) | Option Ex | 11,578 | 7.03 | 81,393 |
| 2021-01-08 | Leggett Thomas (Chief Financial Officer) | Sale | 3,000 | 33.94 | 101,820 |
| 2021-01-08 | Leggett Thomas (Chief Financial Officer) | Option Ex | 3,000 | 10.86 | 32,580 |
| 2021-01-04 | Roberts Christopher D. (Chief Scientific Officer) | Sale | 2,500 | 31.54 | 78,857 |
| 2021-01-04 | Roberts Christopher D. (Chief Scientific Officer) | Option Ex | 2,500 | 10.86 | 27,150 |
| 2021-01-04 | Epstein David M. (See Remarks) | Sale | 12,000 | 31.39 | 376,728 |
| 2021-01-04 | Epstein David M. (See Remarks) | Option Ex | 3,000 | 6.42 | 19,260 |
| 2020-12-28 | Hatzis-schoch Brent (See Remarks) | Option Ex | 5,400 | 3.20 | 17,280 |
| 2020-12-15 | Roberts Christopher D. (Chief Scientific Officer) | Option Ex | 3,200 | 10.86 | 34,752 |
| 2020-12-15 | Epstein David M. (See Remarks) | Option Ex | 2,500 | 6.42 | 16,050 |
| 2020-12-14 | Hatzis-schoch Brent (See Remarks) | Sale | 4,078 | 34.95 | 142,522 |
| 2020-12-14 | Hatzis-schoch Brent (See Remarks) | Option Ex | 4,078 | 3.20 | 13,049 |
| 2020-12-08 | Leggett Thomas (Chief Financial Officer) | Sale | 3,000 | 33.66 | 100,983 |
| 2020-12-08 | Leggett Thomas (Chief Financial Officer) | Option Ex | 3,000 | 10.86 | 32,580 |
| 2020-12-03 | Roberts Christopher D. (Chief Scientific Officer) | Sale | 2,500 | 32.42 | 81,054 |
| 2020-12-03 | Roberts Christopher D. (Chief Scientific Officer) | Option Ex | 2,500 | 10.86 | 27,150 |
| 2020-12-01 | Epstein David M. (See Remarks) | Sale | 12,000 | 33.04 | 396,527 |
| 2020-12-01 | Epstein David M. (See Remarks) | Option Ex | 3,000 | 6.42 | 19,260 |
| 2020-11-30 | Versant Vantage I, L.p. (10% Owner) | Sale | 10,393 | 33.65 | 349,693 |
| 2020-11-30 | Bolzon Bradley J Phd (Director) | Sale | 10,393 | 33.65 | 349,693 |
| 2020-11-19 | Versant Vantage I, L.p. (10% Owner) | Sale | 130,017 | 33.01 | 4,291,861 |
| 2020-11-19 | Bolzon Bradley J Phd (Director) | Sale | 130,017 | 33.01 | 4,291,861 |
| 2020-11-18 | Versant Vantage I, L.p. (10% Owner) | Sale | 536 | 33.09 | 17,738 |
| 2020-11-18 | Bolzon Bradley J Phd (Director) | Sale | 536 | 33.09 | 17,738 |
| 2020-11-17 | Versant Vantage I, L.p. (10% Owner) | Sale | 4,194 | 33.05 | 138,611 |
| 2020-11-17 | Bolzon Bradley J Phd (Director) | Sale | 4,194 | 33.05 | 138,611 |
| 2020-11-16 | Versant Vantage I, L.p. (10% Owner) | Sale | 200 | 33.01 | 6,602 |
| 2020-11-16 | Bolzon Bradley J Phd (Director) | Sale | 200 | 33.01 | 6,602 |
| 2020-11-13 | Versant Vantage I, L.p. (10% Owner) | Sale | 4,500 | 33.92 | 152,653 |
| 2020-11-13 | Bolzon Bradley J Phd (Director) | Sale | 4,500 | 33.92 | 152,653 |
| 2020-11-12 | Versant Vantage I, L.p. (10% Owner) | Sale | 15,598 | 34.34 | 535,635 |
| 2020-11-12 | Hatzis-schoch Brent (See Remarks) | Sale | 4,078 | 34.24 | 139,618 |
| 2020-11-12 | Hatzis-schoch Brent (See Remarks) | Option Ex | 4,078 | 3.20 | 13,049 |
| 2020-11-12 | Bolzon Bradley J Phd (Director) | Sale | 15,598 | 34.34 | 535,635 |
| 2020-11-11 | Roberts Christopher D. (Chief Scientific Officer) | Sale | 5,000 | 34.90 | 174,500 |
| 2020-11-11 | Roberts Christopher D. (Chief Scientific Officer) | Option Ex | 5,000 | 10.86 | 54,300 |
| 2020-11-11 | Versant Vantage I, L.p. (10% Owner) | Sale | 12,617 | 34.40 | 433,999 |
| 2020-11-11 | Bolzon Bradley J Phd (Director) | Sale | 12,617 | 34.40 | 433,999 |
| 2020-11-10 | Versant Vantage I, L.p. (10% Owner) | Sale | 26,966 | 33.81 | 911,747 |
| 2020-11-10 | Bolzon Bradley J Phd (Director) | Sale | 26,966 | 33.81 | 911,747 |
| 2020-11-09 | Leggett Thomas (Chief Financial Officer) | Sale | 3,000 | 32.96 | 98,892 |
| 2020-11-09 | Leggett Thomas (Chief Financial Officer) | Option Ex | 3,000 | 10.86 | 32,580 |
| 2020-11-09 | Versant Vantage I, L.p. (10% Owner) | Sale | 6,300 | 33.06 | 208,252 |
| 2020-11-09 | Bolzon Bradley J Phd (Director) | Sale | 6,300 | 33.06 | 208,252 |
| 2020-11-06 | Versant Vantage I, L.p. (10% Owner) | Sale | 3,100 | 33.13 | 102,699 |
| 2020-11-06 | Bolzon Bradley J Phd (Director) | Sale | 3,100 | 33.13 | 102,699 |
| 2020-11-05 | Versant Vantage I, L.p. (10% Owner) | Sale | 8,848 | 33.15 | 293,284 |
| 2020-11-05 | Bolzon Bradley J Phd (Director) | Sale | 8,848 | 33.15 | 293,284 |
| 2020-11-04 | Versant Vantage I, L.p. (10% Owner) | Sale | 2,500 | 33.14 | 82,840 |
| 2020-11-04 | Bolzon Bradley J Phd (Director) | Sale | 2,500 | 33.14 | 82,840 |
| 2020-11-03 | Roberts Christopher D. (Chief Scientific Officer) | Sale | 2,500 | 31.95 | 79,872 |
| 2020-11-03 | Roberts Christopher D. (Chief Scientific Officer) | Option Ex | 2,500 | 10.86 | 27,150 |
| 2020-11-02 | Epstein David M. (See Remarks) | Sale | 12,000 | 31.50 | 378,048 |
| 2020-11-02 | Epstein David M. (See Remarks) | Option Ex | 3,000 | 6.42 | 19,260 |
| 2020-10-27 | Versant Vantage I, L.p. (10% Owner) | Sale | 800 | 33.03 | 26,426 |
| 2020-10-27 | Bolzon Bradley J Phd (Director) | Sale | 800 | 33.03 | 26,426 |
| 2020-10-26 | Versant Vantage I, L.p. (10% Owner) | Sale | 8,103 | 33.30 | 269,870 |
| 2020-10-26 | Bolzon Bradley J Phd (Director) | Sale | 8,103 | 33.30 | 269,870 |
| 2020-10-19 | Versant Vantage I, L.p. (10% Owner) | Sale | 4,233 | 33.43 | 141,513 |
| 2020-10-19 | Bolzon Bradley J Phd (Director) | Sale | 4,233 | 33.43 | 141,513 |
| 2020-10-16 | Versant Vantage I, L.p. (10% Owner) | Sale | 8,713 | 33.57 | 292,521 |
| 2020-10-16 | Bolzon Bradley J Phd (Director) | Sale | 8,713 | 33.57 | 292,521 |
| 2020-10-15 | Versant Vantage I, L.p. (10% Owner) | Sale | 2,800 | 33.03 | 92,495 |
| 2020-10-15 | Bolzon Bradley J Phd (Director) | Sale | 2,800 | 33.03 | 92,495 |
| 2020-10-14 | Versant Vantage I, L.p. (10% Owner) | Sale | 5,501 | 33.09 | 182,033 |
| 2020-10-14 | Bolzon Bradley J Phd (Director) | Sale | 5,501 | 33.09 | 182,033 |
| 2020-10-13 | Versant Vantage I, L.p. (10% Owner) | Sale | 11,739 | 33.39 | 391,988 |
| 2020-10-13 | Bolzon Bradley J Phd (Director) | Sale | 11,739 | 33.39 | 391,988 |
| 2020-10-12 | Versant Vantage I, L.p. (10% Owner) | Sale | 400 | 33.11 | 13,243 |
| 2020-10-12 | Hatzis-schoch Brent (See Remarks) | Sale | 4,078 | 33.18 | 135,320 |
| 2020-10-12 | Hatzis-schoch Brent (See Remarks) | Option Ex | 4,078 | 3.20 | 13,049 |
| 2020-10-12 | Bolzon Bradley J Phd (Director) | Sale | 400 | 33.11 | 13,243 |
| 2020-10-09 | Versant Vantage I, L.p. (10% Owner) | Sale | 3,800 | 33.67 | 127,934 |
| 2020-10-09 | Bolzon Bradley J Phd (Director) | Sale | 3,800 | 33.67 | 127,934 |
| 2020-10-08 | Leggett Thomas (Chief Financial Officer) | Sale | 3,000 | 33.52 | 100,575 |
| 2020-10-08 | Leggett Thomas (Chief Financial Officer) | Option Ex | 3,000 | 10.86 | 32,580 |
| 2020-10-08 | Versant Vantage I, L.p. (10% Owner) | Sale | 18,425 | 33.46 | 616,574 |
| 2020-10-08 | Bolzon Bradley J Phd (Director) | Sale | 18,425 | 33.46 | 616,574 |
| 2020-10-07 | Versant Vantage I, L.p. (10% Owner) | Sale | 27,836 | 33.56 | 934,092 |
| 2020-10-07 | Bolzon Bradley J Phd (Director) | Sale | 27,836 | 33.56 | 934,092 |
| 2020-10-06 | Versant Vantage I, L.p. (10% Owner) | Sale | 18,090 | 33.26 | 601,655 |
| 2020-10-06 | Bolzon Bradley J Phd (Director) | Sale | 18,090 | 33.26 | 601,655 |
| 2020-10-05 | Roberts Christopher D. (Chief Scientific Officer) | Sale | 2,500 | 31.59 | 78,987 |
| 2020-10-05 | Roberts Christopher D. (Chief Scientific Officer) | Option Ex | 2,500 | 10.86 | 27,150 |
| 2020-10-01 | Epstein David M. (See Remarks) | Sale | 12,000 | 30.33 | 363,960 |
| 2020-10-01 | Epstein David M. (See Remarks) | Option Ex | 3,000 | 6.42 | 19,260 |
| 2020-09-30 | Ingram Robert Alexander (Director) | Buy | 5,000 | 30.46 | 152,285 |
| 2020-09-14 | Leggett Thomas (Chief Financial Officer) | Sale | 3,000 | 31.00 | 93,000 |
| 2020-09-14 | Leggett Thomas (Chief Financial Officer) | Option Ex | 3,000 | 10.86 | 32,580 |
| 2020-09-14 | Hatzis-schoch Brent (See Remarks) | Sale | 4,078 | 31.58 | 128,766 |
| 2020-09-14 | Hatzis-schoch Brent (See Remarks) | Option Ex | 4,078 | 3.20 | 13,049 |
| 2020-09-03 | Roberts Christopher D. (Chief Scientific Officer) | Sale | 2,500 | 29.29 | 73,230 |
| 2020-09-03 | Roberts Christopher D. (Chief Scientific Officer) | Option Ex | 2,500 | 10.86 | 27,150 |
| 2020-08-11 | Versant Vantage I, L.p. (10% Owner) | Sale | 7,575 | 33.08 | 250,588 |
| 2020-08-11 | Bolzon Bradley J Phd (Director) | Sale | 7,575 | 33.08 | 250,588 |
| 2020-08-10 | Versant Vantage I, L.p. (10% Owner) | Sale | 6,217 | 33.04 | 205,397 |
| 2020-08-10 | Bolzon Bradley J Phd (Director) | Sale | 6,217 | 33.04 | 205,397 |
| 2020-02-03 | Versant Vantage I, L.p. (10% Owner) | Buy | 894,736 | 19.00 | 16,999,984 |
| 2020-02-03 | Hatzis-schoch Brent (See Remarks) | Buy | 3,000 | 19.00 | 57,000 |
| 2020-02-03 | Shah Rajeev M. (Director) | Buy | 1,000,000 | 19.00 | 19,000,000 |
| 2020-02-03 | Behbahani Ali (Director) | Buy | 800,000 | 19.00 | 15,200,000 |
| 2020-02-03 | Bolzon Bradley J Phd (Director) | Buy | 894,736 | 19.00 | 16,999,984 |
| 2020-02-03 | Deerfield Partners, L.p. | Buy | 400,000 | 19.00 | 7,600,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of BDTX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Black Diamond Therapeutics, Inc. (symbol BDTX, CIK number 1701541) see the Securities and Exchange Commission (SEC) website.